Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gritstone Jumps Into COVID-19 Vaccine Race, Eyeing Mutant Strains

Potentially Resistant Strains Raise Worries

Executive Summary

The company is developing a vaccine with both adenoviral and mRNA technology that could potentially overcome resistance mutations on the SARS-CoV-2 spike protein.

You may also be interested in...



Coronavirus Update: Pfizer/BioNTech Send In Data For Booster Approval

Pfizer and BioNTech sent in Phase I data for a third dose of BNT162b2 to support future licensure, Gritstone bio will work with CEPI to develop its second-generation vaccine in South Africa and other areas, and Roche Genentech expects a shortage of the drug Actemra to last for several weeks amid a surge in cases.

Gritstone, Gilead Partner To Develop Therapeutic HIV Vaccine

Gritstone will supply the same type of prime-boost vaccine technology it is applying to SARS-CoV-2, and Gilead will supply its own antigens, with the goal of curing HIV.

Regeneron Antibodies Prevent Symptomatic COVID-19 In Interim Phase III Data

The company said data show a lower overall infection rate and no symptomatic infections among participants receiving the drug, compared with placebo.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143659

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel